Radiation Oncology/Epidemiology/Survival

From Wikibooks, open books for an open world
Jump to navigation Jump to search


Cancer Survival Data


Disease Median OS 1-year OS 2-year OS 5-year OS 10-year OS
Chordoma
    Overall (SEER data) 6.3 years     68% 40%
Glioma
  Low Grade (WHO II)
    RT alone (EORTC 22844) ~6 years     59%  
    RT alone (NCCTG) ~9 years   94% 72%  
    Observation (EORTC 22845) 7.4 years     66%  
  High Grade (WHO III)
    RT alone (RTOG 9402) 4.7 years     46%  
    RT alone (EORTC 26951) 3.4 years     37%  
  High Grade (WHO IV)
    Observation (BTCG 69-01) 3.2 months        
    RT alone (BTCG 69-01) 8.1 months        
Pancreas
  Resectable
    Surgery only (CONKO-001) 1.7 years     9%  
    Adjuvant 5FU/RT (GITSG 9173) 1.7 years   42%    
    Adjuvant 5FU/RT/Chemo (ESPAC-1) 1.7 years        
    Adjuvant GEM-RT/5-FU/GEM (RTOG 9704) 1.7 years        
    Adjuvant GEM (CONKO-001) 1.9 years     21%  
  Unresectable
    No treatment ~4 months        
    Palliative bypass 6-7 months        
    RT/5-FU (FFCD-SFRO) 9 months 32%      
    RT/GEM (ECOG E4201) 11 months        
    GEM (FFCD-SFRO) 13 months 53%      
    RT/GEM (Taipei) 14 months 56% 15%    
    RT/TNFerade(PACT) 1.4 years 71%      
Prostate
  Early Stage (cT1-T2)
    Watchful waiting (SPCG-4)         86%
    Surgery (SPCG-4)         91%
NSCLC
  Early Stage Operable
    Surgery (Stage I) composite       65%  
    Surgery (Stage I) Brazil       95%  
    Conventional RT (Stage I) composite       20%  
    SBRT (Stage I) Japan       83%  
    Surgery (Stage II)       45%  
Spinal Cord Compression
    RT Alone (Patchell) 3 months
    Surgery + RT (Patchell) 4 months